Gabather AB

Equities

GABA

SE0010869552

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 08:43:21 07/06/2024 pm IST			5-day change	1st Jan Change
1.815 ^SEK	-0.27%		+9.67%	+28.72%

30/05	Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/04	Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	CI

Gabather AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021

April 23, 2021 at 11:30 am IST

Gabather AB publ announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was SEK 3.456 million compared to SEK 4.320 million a year ago. Net loss was SEK 3.456 million compared to SEK 4.320 million a year ago. Basic loss per share from continuing operations was SEK 0.26 compared to SEK 0.32 a year ago.

Latest news about Gabather AB

Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2024	30/05	CI
Gabather AB Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct A Clinical Phase II Study with GT-002	10/04	CI
Gabather Submits Two US Patent Applications for GT-002 Use in Psychiatric Disorders	18/03	MT
Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric Disorders	18/03	CI
Gabather AB Reports Initial Positive Results from the EEG/fMRI Target Engagement Study	07/03	CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002	14/12	CI
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/11	CI
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers	12/23/12	CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17	CI
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Gabather AB Receives Notice of Approval from the Japanese Patent Office for National Phase Application	13/23/13	CI
Gabather AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	08/23/08	CI
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/22/03	CI
Gabather AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	31/22/31	CI
Gabather Secures Notice Of Allowance For US Patent Claims Covering Neuropsychiatric Drug Synthesis	07/22/07	MT
Gabather Receives Approval to Start the EEG/fMRI Target Engagement Study with the Drug Candidate GT-002	17/22/17	CI
Gabather AB Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
Gabather AB Reports Earnings Results for the Full Year Ended December 31, 2021	17/22/17	CI
Gabather AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	17/22/17	CI
Gabather AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	28/21/28	CI
Gabather AB Reports Earnings Results for the Second Quarter Ended June 30, 2021	26/21/26	CI
Gabather AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	23/21/23	CI
Gabather AB Gives Clinical Trial Update	25/21/25	CI
Gabather AB Enters into A Research Collaboration to Investigate GT-002	24/21/24	CI

Chart Gabather AB

Duration

Period

More charts

Company Profile

Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimerâs disease.

Sector

Biotechnology & Medical Research

Calendar

28/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GABATHER AB	+28.72%	3.3M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.57B
ARGENX SE	+3.23%	22.82B
GENMAB A/S	-10.44%	18.19B
WUXI APPTEC CO., LTD.	-41.74%	16.54B
BEIGENE, LTD.	-13.31%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.39B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.1B

Bio Therapeutic Drugs